A GUIDE TO
TRUST THE POWER OF PREVENTION < 2 > WHY IS PREVENTION IMPORTANT? Hereditary angioedema (HAE) symptoms can range in severity. Some attacks may be mild or temporarily disabling, but others can become more dangerous due to throat swelling. Severe swelling of the throat can make breathing difficult and result in a life-threatening emergency. Prevention can be a good option to help reduce the frequency and severity of attacks. It is important to note that treatment plans, when discussed, should be individualized to your needs. Guidelines recommend talking to your doctor about the frequency and severity of your HAE attacks when planning your treatment. Remember, the location of an attack may have an impact on severity, eg, an airway attack is likely to be considered severe. CINRYZE (C1 esterase inhibitor [human]) is approved by the FDA to help prevent swelling and/or painful attacks in teenagers and adults with HAE. THINK ABOUT WHY YOU HAVE CHOSEN CINRYZE TO PROACTIVELY TREAT YOUR HAE
TRUST THE POWER OF PREVENTION < 3 > Dariela, a real HAE patient TRUST THE POWER OF PREVENTION WITH CINRYZE Indication CINRYZE (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks in teenagers and adults with Hereditary Angioedema (HAE). You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product. Please see additional on adjacent pages. Please see the Full Prescribing Information available at www.cinryze.com.
TRUST THE POWER OF PREVENTION < 4 > HOW DOES CINRYZE WORK? HAE is caused by an insufficient amount of or defective C1 esterase inhibitor, a protein in the blood that helps to prevent swelling experienced during HAE attacks. UNTREATED PERSON WITH HAE People with HAE have an insufficient amount of or defective C1 esterase inhibitor, which contributes to a cascade of events in the body. This leads to increased production of bradykinin, a protein that causes your vessels to leak fluid into the tissues. Fluid moves out through the leaky blood vessel walls and builds up between the tissue cells underneath the skin, which results in localized swelling. Red blood cell Tissue cell Blood vessel wall C1 esterase inhibitor Bradykinin Fluid leakage Tell your healthcare provider about all of your medical conditions, including if you: have an indwelling catheter/access device in one of your veins. have a history of blood clots, heart disease, or stroke. are taking birth control pills or androgens. are pregnant or planning to become pregnant. It is not known if CINRYZE (C1 esterase inhibitor [human]) can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if CINRYZE passes into your milk and if it can harm your baby. Please see additional on adjacent pages. Please see the Full Prescribing Information available at www.cinryze.com.
CINRYZE (C1 esterase inhibitor [human]), which is administered by intravenous (IV) infusion, increases plasma levels of C1 inhibitor activity. PERSON WITH HAE RECEIVING CINRYZE CINRYZE increases your body s supply of functional C1 esterase inhibitor, which may reduce the production of bradykinin and control the swelling associated with HAE. Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: wheezing difficulty breathing chest tightness turning blue (look at lips and gums) fast heartbeat swelling of the face faintness rash hives
TRUST THE POWER OF PREVENTION < 6 > CINRYZE HAS BEEN PROVEN EFFECTIVE The safety and effectiveness of CINRYZE (C1 esterase inhibitor [human]) were evaluated in a 24-week clinical trial of 22 patients. Patients in the study were diagnosed with HAE and had a history of at least two attacks per month. Patients were divided into two groups: one group received CINRYZE for the first 12 weeks and switched to placebo for the last 12 weeks; the other group received placebo for the first 12 weeks and switched to CINRYZE for the last 12 weeks. The most common side effects observed in the clinical trial were rash, headache, nausea, and vomiting. No patients discontinued treatment because of an adverse reaction. HOW WAS EFFECTIVENESS MEASURED? The main measure was to determine the number of attacks experienced by each patient when taking CINRYZE compared with the number of attacks experienced by each patient when taking placebo. Serious blood clots may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: pain and/or swelling of an arm or leg with warmth over the affected area discoloration of an arm or leg unexplained shortness of breath chest pain or discomfort that worsens on deep breathing unexplained rapid heart rate numbness or weakness on one side of the body Please see additional on adjacent pages. Please see the Full Prescribing Information available at www.cinryze.com.
CINRYZE HELPED PREVENT ATTACKS IN MOST PATIENTS While on CINRYZE (C1 esterase inhibitor [human]), the majority of patients had fewer attacks The response to CINRYZE varied Of the 22 patients, 4 had no attacks and 2 had more attacks NUMBER OF ATTACKS Mean (average) Min Max CINRYZE (22 PATIENTS) 6.1* 0 17 PLACEBO (22 PATIENTS) 12.7 6 22 *P<0.0001 vs placebo Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The most common side effects seen with CINRYZE were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You can also report side effects to Shire Medical Information at 1-866-888-0660.
TRUST THE POWER OF PREVENTION < 8 > Since having my first CINRYZE infusion...i am happy to say that the frequency of my attacks has been reduced. Jeanie, a real HAE patient
CINRYZE HELPED TO REDUCE THE SEVERITY AND DURATION OF ATTACKS During treatment with CINRYZE (C1 esterase inhibitor [human]), compared to placebo, patients experienced: Decrease in the average duration of attacks Attacks lasted 2.1 days while taking CINRYZE vs. 3.4 days while taking placebo (p<0.01) Fewer days of swelling 66% reduction in days of swelling (p<0.01) Decrease in the average severity of attacks On a 3-point scale (1=Mild, 2=Moderate, 3=Severe), attacks while taking CINRYZE were ranked as less severe than were attacks while taking placebo (1.3 vs. 1.9, p<0.01) REMEMBER THAT PREVENTION WITH CINRYZE CAN HELP REDUCE THE BURDEN OF YOUR HAE ATTACKS It can be helpful to have a treatment plan in case of emergency. Discuss your options with your healthcare provider. Indication CINRYZE (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks in teenagers and adults with Hereditary Angioedema (HAE). You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product. Please see additional on adjacent pages. Please see the Full Prescribing Information available at www.cinryze.com.
TRUST THE POWER OF PREVENTION < 10 > HOW IS CINRYZE MADE? CINRYZE (C1 esterase inhibitor [human]) is made from purified human blood that is collected from US plasma donors at US-licensed collection centers. Products made from human blood may contain infectious agents. CINRYZE goes through a complex purification process. The process is designed to help protect you by reducing the risk of transmitting infectious disease. The specific steps to minimize the risk of transmitting an infectious agent include careful donor screening, testing for the presence of viruses, pasteurization and nanofiltration. Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The most common side effects seen with CINRYZE were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You can also report side effects to Shire Medical Information at 1-866-888-0660. Please see additional on adjacent pages. Please see the Full Prescribing Information available at www.cinryze.com.
After weighing the benefits and possible side effects with my specialist, I was convinced that CINRYZE might help. Scott, a real HAE patient
TRUST THE POWER OF PREVENTION < 12 > HOW IS CINRYZE ADMINISTERED? The administration of CINRYZE (C1 esterase inhibitor [human]) requires a needle to be placed in a vein in your arm. CINRYZE should be prepared and administered at room temperature, and it takes about 10 minutes to complete the injection. DOSING OF CINRYZE DOSE 1000 U intravenous (2) 500 U vials of CINRYZE + (2) 5 ml vials of Sterile Water for Injection, USP DOSING REGIMEN Single dose can be administered every 3 or 4 days INFUSION RATE 1 ml/min (10 minutes) UNDERSTAND THAT MISSING A DOSE OF CINRYZE CAN RESULT IN BREAKTHROUGH ATTACKS If you miss a dose of CINRYZE, infuse as soon as you remember and call your healthcare provider to adjust your treatment schedule as needed. Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: wheezing difficulty breathing chest tightness turning blue (look at lips and gums) fast heartbeat swelling of the face faintness rash hives Please see additional on adjacent pages. Please see the Full Prescribing Information available at www.cinryze.com.
FLEXIBLE ADMINISTRATION OPTIONS There are many options to consider when administering CINRYZE (C1 esterase inhibitor [human]). Talk to your healthcare provider about which option is best for you and your lifestyle. Administration by a healthcare provider at an infusion center, a doctor s office, or in your home STORING CINRYZE CINRYZE should be stored at 2 C to 25 C (36 F to 77 F) CINRYZE should be protected from light Once CINRYZE is prepared, it must be used within 3 hours Administration by a trained family member or caregiver Self-administration Path to Independence is a training and support program designed to help teach patients, family members, or caregivers how to self-administer or administer CINRYZE. For more information, contact your OnePath Case Manager at 1-866-888-0660. STAY ON TRACK WITH THE TREATMENT SCHEDULE THAT YOU AND YOUR DOCTOR AGREED ON Patients should only self-administer after being trained by a healthcare provider. Serious blood clots may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: pain and/or swelling of an arm or leg with warmth over the affected area discoloration of an arm or leg unexplained shortness of breath chest pain or discomfort that worsens on deep breathing unexplained rapid heart rate numbness or weakness on one side of the body
TRUST THE POWER OF PREVENTION < 14 > ADDITIONAL RESOURCES The US Hereditary Angioedema Association (HAEA) is another great resource for people living with HAE and for their families. Visit the HAEA website at www.haea.org to learn about the wide variety of services offered by the organization. You, Me & HAE, a mentor program, can pair you with a mentor who also has HAE and is currently on therapy with CINRYZE (C1 esterase inhibitor [human]). Contact your OnePath Case Manager to request a mentor. TAKE ADVANTAGE OF PERSONALIZED PRODUCT SERVICES WITH ONEPATH TO MAINTAIN YOUR INDEPENDENCE The most common side effects seen with CINRYZE were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You can also report side effects to Shire Medical Information at 1-866-888-0660. Please see additional on adjacent pages. Please see the Full Prescribing Information available at www.cinryze.com.
QUESTIONS? Your OnePath Case Manager can help by: Answering questions about CINRYZE (C1 esterase inhibitor [human]) Helping you gain access to therapy Navigating insurance coverage Finding infusion centers while you are traveling Providing ongoing support and more! Call your OnePath Case Manager at 1-866-888-0660 for more information. Through the OnePath product support service, I have my own Case Manager who has been a great help. He always keeps me informed. Dariela, a real HAE patient Indication CINRYZE (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks in teenagers and adults with Hereditary Angioedema (HAE). You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product.
TRUST THE POWER OF PREVENTION WITH CINRYZE THINK ABOUT WHY YOU HAVE CHOSEN CINRYZE (C1 ESTERASE INHIBITOR [HUMAN]) TO PROACTIVELY TREAT YOUR HAE REMEMBER THAT PREVENTION WITH CINRYZE CAN HELP REDUCE THE BURDEN OF YOUR HAE ATTACKS UNDERSTAND THAT MISSING A DOSE OF CINRYZE CAN RESULT IN BREAKTHROUGH ATTACKS STAY ON TRACK WITH THE TREATMENT SCHEDULE THAT YOU AND YOUR DOCTOR AGREED ON TAKE ADVANTAGE OF PERSONALIZED PRODUCT SERVICES WITH ONEPATH TO MAINTAIN YOUR INDEPENDENCE FOR MORE INFORMATION, VISIT WWW.CINRYZE.COM. Please see the inside and the Full Prescribing Information available at www.cinryze.com. CINRYZE, OnePath, Path to Independence, and the associated logos are either registered trademarks or trademarks of Shire or its affiliates. 2016 Shire. All rights reserved. S11234 02/2016